BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

Report an Adverse Event

To report an adverse event/reaction and/or product complaint to BDSI, call 1-800-469-0261 and select option 1. Or email the information requested below to drugsafety@bdsi.com.

When choosing this option please have the following information ready:

  • Identifiable reporter
  • Identifiable patient (gender)
  • Adverse reaction and/or product complaint
  • Suspect lot number and/or dosing information
  • Callback number and/or email

To report an adverse event/reaction directly to FDA’s MedWatch program, call 1-800-FDA-1088 (1-800-332-1088) or go to www.fda.gov/Safety/MedWatch.

If you wish to be contacted by your local BDSI representative, call 1-800-469-0261 and select option 6.

BDSI routinely collects and analyzes safety information on our products, including reports from healthcare professionals and patients about Adverse Events and Product Complaints. We submit reports as appropriate to the U.S. Food and Drug Administration (FDA) which reviews these reports.

Recent BDSI News

January 15, 2021

Oral Presentation of Data from Phase I Safety Study & Secondary Respiratory Outcomes Comparing BELBUCA ® to Oxycodone on January 16 from 1:10pm – 2:10pm CT RALEIGH, N.C. , Jan. 15, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty

Read more
November 20, 2020

RALEIGH, N.C. , Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeff Bailey , Chief Executive Officer, and

Read more
November 11, 2020

RALEIGH, N.C. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Chief Executive Officer, and

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
January 22, 2021BDSI $4.14/ - -1.66%
Data provided by Nasdaq. Minimum 15 minutes delayed.